Atreca Stock (NASDAQ:BCEL)


ForecastOwnershipChart

Previous Close

$0.09

52W Range

$0.05 - $1.20

50D Avg

$0.09

200D Avg

$0.20

Market Cap

$3.57M

Avg Vol (3M)

$267.00K

Beta

1.03

Div Yield

-

BCEL Company Profile


Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients. It also developing APN-122597, a receptor tyrosine kinase that target tumor tissues; and ATRC-501/MAM01, that targets the circumsporozoite protein of Plasmodium falciparum for the treatment of malaria. It has a collaboration and license agreement with Xencor, Inc. for research, development, and commercialization of novel CD3 bispecific antibodies in oncology; licensing agreement with the Bill & Melinda Gates Medical Research Institute for the development and commercialization of MAM01/ATRC-501 for the prevention of malaria. Atreca, Inc. was incorporated in 2010 and is based in San Carlos, California.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

90

IPO Date

Jun 20, 2019

Website

BCEL Performance


Latest Earnings Call Transcripts


Q4 22Mar 29, 23 | 8:36 PM
Q4 21Mar 04, 22 | 3:45 PM

Peer Comparison


TickerCompany
RVMDRevolution Medicines, Inc. Warrant
STOKStoke Therapeutics, Inc.
ALECAlector, Inc.
BDTXBlack Diamond Therapeutics, Inc.
PASGPassage Bio, Inc.
FIXXQ32 Bio Inc.